---
input_text: 'Wilson disease: symptomatic liver therapy. Wilson disease leads to symptomatic
  impairment of liver function or liver cirrhosis. Strict adherence to decoppering
  agents is essential in these patients. Secondary prevention of additional hepatic
  damage by avoidance of other toxic substances (e.g., alcohol, drugs) and sufficient
  calorie intake is recommended. Routine examinations in cirrhotic patients include
  screening for signs of portal hypertension (esophagus varices), development of ascites,
  and hepatic encephalopathy. Where varices are present, primary or secondary preventive
  interventions may include treatment with nonselective beta-blockers or variceal
  ligation, similar to the approach in patients with liver cirrhosis due to other
  etiologies. For patients presenting with ascites, diuretics are the treatment of
  choice. Spontaneous bacterial peritonitis can be diagnosed by paracentesis and should
  be treated with antibiotics. Liver cirrhosis can also lead to accumulation of neurotoxins
  causing hepatic encephalopathy. It is characterized by unspecific neuropsychiatric
  impairment and is treated with laxatives and nonresorbable antibiotics. The best
  prophylaxis is regular defecation. Patients with liver cirrhosis are susceptible
  for bacterial infections of any cause and sepsis is one of the leading causes of
  death in these patients. In advanced stages of cirrhosis renal function impairment
  is a common feature. The hepatorenal syndrome shows a high mortality. Where Wilson
  disease patients have decompensated liver cirrhosis, liver transplantation should
  be evaluated.'
raw_completion_output: |-
  primary_disease: Wilson disease
  medical_actions: Strict adherence to decoppering agents; avoidance of other toxic substances; sufficient calorie intake; screening for signs of portal hypertension; screening for development of ascites; screening for hepatic encephalopathy; treatment with nonselective beta-blockers; variceal ligation; treatment with diuretics; treatment with antibiotics; treatment with laxatives; treatment with nonresorbable antibiotics; regular defecation; liver transplantation
  symptoms: symptomatic impairment of liver function; liver cirrhosis; portal hypertension; ascites; hepatic encephalopathy; spontaneous bacterial peritonitis; neuropsychiatric impairment; bacterial infections; sepsis; renal function impairment; hepatorenal syndrome
  chemicals: nonselective beta-blockers; diuretics; antibiotics; laxatives; nonresorbable antibiotics
  action_annotation_relationships: Strict adherence to decoppering agents PREVENTS additional hepatic damage IN Wilson disease; avoidance of other toxic substances PREVENTS additional hepatic damage IN Wilson disease; sufficient calorie intake PREVENTS additional hepatic damage IN Wilson disease; treatment with nonselective beta-blockers PREVENTS portal hypertension IN Wilson disease; variceal ligation PREVENTS portal hypertension IN Wilson disease; treatment with diuretics TREATS ascites IN Wilson disease; treatment with antibiotics TREATS spontaneous bacterial peritonitis IN Wilson disease; treatment with laxatives TREATS hepatic encephalopathy IN Wilson disease; treatment with nonresorbable antibiotics TREATS hepatic encephalopathy IN Wilson disease; regular defecation PREVENTS hepatic encephalopathy IN Wilson disease; liver transplantation TREATS decompensated liver cirrhosis IN Wilson disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  liver transplantation TREATS decompensated liver cirrhosis IN Wilson disease

  ===

extracted_object:
  primary_disease: MONDO:0010200
  medical_actions:
    - Strict adherence to decoppering agents
    - avoidance of other toxic substances
    - sufficient calorie intake
    - screening for signs of portal hypertension
    - screening for development of ascites
    - screening for hepatic encephalopathy
    - treatment with nonselective beta-blockers
    - variceal ligation
    - MAXO:0000165
    - treatment with antibiotics
    - treatment with laxatives
    - treatment with nonresorbable antibiotics
    - regular defecation
    - MAXO:0001175
  symptoms:
    - symptomatic impairment of liver function
    - HP:0001394
    - HP:0001409
    - HP:0001541
    - HP:0002480
    - spontaneous bacterial peritonitis
    - neuropsychiatric impairment
    - bacterial infections
    - HP:0100806
    - renal function impairment
    - hepatorenal syndrome
  chemicals:
    - nonselective beta-blockers
    - CHEBI:35498
    - CHEBI:33281
    - CHEBI:50503
    - nonresorbable antibiotics
  action_annotation_relationships:
    - subject: Strict adherence to decoppering agents
      predicate: PREVENTS
      object: additional hepatic damage
      qualifier: MONDO:0010200
      subject_extension: decoppering agents
    - subject: avoidance of other toxic substances
      predicate: PREVENTS
      object: additional hepatic damage
      qualifier: MONDO:0010200
    - subject: sufficient calorie intake
      predicate: PREVENTS
      object: additional hepatic damage
      qualifier: MONDO:0010200
    - subject: treatment
      predicate: PREVENTS
      object: HP:0001409
      qualifier: MONDO:0010200
      subject_qualifier: with
      subject_extension: nonselective beta-blockers
    - subject: variceal ligation
      predicate: PREVENTS
      object: HP:0001409
      qualifier: MONDO:0010200
    - subject: treatment
      predicate: TREATS
      object: HP:0001541
      qualifier: MONDO:0010200
      subject_qualifier: with
      subject_extension: CHEBI:35498
    - subject: treatment
      predicate: TREATS
      object: spontaneous bacterial peritonitis
      qualifier: MONDO:0010200
      subject_qualifier: with
      subject_extension: CHEBI:33281
    - subject: treatment with laxatives
      predicate: TREATS
      object: HP:0002480
      qualifier: MONDO:0010200
      subject_extension: CHEBI:50503
    - subject: treatment
      predicate: TREATS
      object: HP:0002480
      qualifier: MONDO:0010200
      subject_extension: nonresorbable antibiotics
    - subject: regular defecation
      predicate: PREVENTS
      object: HP:0002480
      qualifier: MONDO:0010200
    - subject: MAXO:0001175
      predicate: TREATS
      object: decompensated liver cirrhosis
      qualifier: MONDO:0010200
named_entities:
  - id: MONDO:0010200
    label: Wilson's disease
  - id: MAXO:0001175
    label: liver transplantation
  - id: HP:0001695
    label: cardiac arrest
  - id: HP:0001685
    label: myocardial fibrosis
  - id: HP:0001663
    label: ventricular fibrillation
  - id: CHEBI:30703
    label: tetrathiomolybdate (TTM)
  - id: CHEBI:35176
    label: Zinc sulphate
  - id: CHEBI:35475
    label: NSAIDs
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0006554
    label: acute liver failure
  - id: HP:0003256
    label: coagulopathy
  - id: HP:0002480
    label: hepatic encephalopathy
  - id: HP:0001337
    label: Tremor
  - id: HP:0001332
    label: Dystonia
  - id: CHEBI:28694
    label: Copper
  - id: HP:0001395
    label: Liver fibrosis
  - id: HP:0001394
    label: Cirrhosis
  - id: CHEBI:39501
    label: trientine
  - id: CHEBI:27363
    label: zinc
  - id: HP:0001410
    label: hepatic dysfunction
  - id: CHEBI:7959
    label: D-penicillamine
  - id: MAXO:0000376
    label: Liver biopsy
  - id: HP:0001404
    label: Hepatocellular necrosis
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:50868
    label: Penicillamine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0001541
    label: ascites
  - id: HP:0001260
    label: Dysarthria
  - id: HP:0001347
    label: Hyperreflexia
  - id: HP:0031843
    label: Bradyphrenia
  - id: HP:0002362
    label: Shuffling gait
  - id: HP:0002300
    label: Mutism
  - id: HP:0001621
    label: Hypophonia
  - id: CHEBI:37153
    label: Calcineurin inhibitors
  - id: CHEBI:8356
    label: Pramipexole
  - id: CHEBI:2618
    label: Amantadine
  - id: HP:0001399
    label: liver failure
  - id: HP:0000952
    label: jaundice
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: MONDO:0013792
    label: Intracerebral Hemorrhage
  - id: HP:0001342
    label: Intracerebral Hemorrhage
  - id: MAXO:0000533
    label: Molecular genetic testing
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002344
    label: worsening neurological symptoms
  - id: HP:0001272
    label: Cerebellar Atrophy
  - id: HP:0012896
    label: abnormal motor evoked potentials (MEPs)
  - id: HP:0001392
    label: liver disease
  - id: HP:0001396
    label: cholestasis
  - id: HP:0001403
    label: macrovesicular steatosis
  - id: CHEBI:8830
    label: rhodanine
  - id: CHEBI:90299
    label: orcein
  - id: MONDO:0018874
    label: Acute Myeloid Leukemia (t-AML or AML-MRC)
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:28680
    label: Cytarabine
  - id: CHEBI:37404
    label: Elemental copper
  - id: CHEBI:16856
    label: Plasma glutathione (GSH)
  - id: CHEBI:53498
    label: Total antioxidant capacity (TAC)
  - id: CHEBI:566274
    label: Malondialdehyde (MDA)
  - id: CHEBI:33697
    label: RNAs
  - id: HP:0000989
    label: itchy skin
  - id: CHEBI:63623
    label: Dimercaptosuccinic acid
  - id: CHEBI:145810
    label: insulin
  - id: HP:0001250
    label: Epileptic seizures
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002315
    label: Headache
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0002878
    label: Acute respiratory failure
  - id: CHEBI:166831
    label: copper chelating agents
  - id: MONDO:0004789
    label: Cholangitis
  - id: MAXO:0010026
    label: zinc supplementation
  - id: CHEBI:16796
    label: Melatonin
  - id: MAXO:0009095
    label: Zinc (Zn) therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:38161
    label: Chelator
  - id: MONDO:0019542
    label: Acute Liver Failure (ALF)
  - id: HP:0002204
    label: Pulmonary embolism
  - id: HP:0100806
    label: Sepsis
  - id: HP:0001944
    label: dehydration
  - id: CHEBI:18248
    label: iron
  - id: CHEBI:18291
    label: manganese
  - id: CHEBI:22984
    label: calcium
  - id: HP:0001081
    label: Cholelithiasis
  - id: HP:0002716
    label: Lymphadenopathy
  - id: MONDO:0100193
    label: End-stage liver diseases
  - id: HP:0002040
    label: Esophageal varices
  - id: HP:0100626
    label: End-stage liver diseases
  - id: MONDO:0017014
    label: children
  - id: MAXO:0009016
    label: Botulinum toxin type A (BoNT-A) injection
  - id: CHEBI:3160
    label: Botulinum toxin type A (BoNT-A)
  - id: HP:0003088
    label: Premature osteoarthritis
  - id: HP:0002885
    label: Mallory-Denk body (MDB) formation
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:16990
    label: Bilirubin
  - id: MONDO:0100192
    label: Liver failure
  - id: HP:0001409
    label: Portal hypertension
  - id: HP:0001402
    label: Hepatocellular carcinoma
  - id: CHEBI:30663
    label: Serum ceruloplasmin (CP)
  - id: HP:0001513
    label: obesity
  - id: CHEBI:16610
    label: spermidine
  - id: CHEBI:27881
    label: resveratrol
  - id: CHEBI:15351
    label: AcCoA
  - id: HP:0001300
    label: Parkinsonism
  - id: CHEBI:62984
    label: zinc acetate
  - id: MAXO:0000165
    label: treatment with diuretics
  - id: CHEBI:35498
    label: diuretics
  - id: CHEBI:33281
    label: antibiotics
  - id: CHEBI:50503
    label: laxatives
